• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Intrauterine devices: a summary of new guidance

The Faculty of Sexual & Reproductive Healthcare (FSRH) Clinical Effectiveness Unit (CEU) has recently published an updated intrauterine device (IUD) guideline, incorporating new evidence-based recommendations alongside refreshed established guidance.1

IUDs are effective and popular long-acting reversible contraception (LARC) used by approximately 159 million users worldwide2 and by approximately 21% of individuals seeking contraception at sexual health services in England.3

Key changesIndications and duration of use of the levonorgestrel IUD

With the addition of Benilexa® to the market in 2021, there are now three 52 mg levonorgestrel IUDs (LNG-IUDs) available in the UK. While the licensed durations and indications of use differ between the 52 mg LNG-IUDs, the FSRH Guideline Development Group advocate that the similarity between the devices and levonorgestrel (LNG) release rates is sufficient to extrapolate evidence from one device to another (table 1).

Indications

Although Mirena® is the only LNG-IUD licensed for endometrial protection…

Read the full article ›

Posted in: Journal Article Abstracts on 06/20/2023 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2026 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice